AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
AbCellera’s share price {$ABCL} climbed about 31% by mid-morning Monday after the biotech shared positive data from a mid-stage hot flashes trial that surpassed Wall Street's expectations. The biotech’s NK3R (neurokinin 3 receptor)-targeting antibody, known ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
